Tag Archives: Juno Therapeutics

January, 2018

22 January
Celgene to Acquire Juno Therapeutics for $9 Billion, Advancing Global Leadership in Cellular Immunotherapy

SUMMIT, N.J. & SEATTLE–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 …
Share

11 December
Juno Therapeutics and Celgene Release Additional Data from its Trial of JCAR017 in Aggressive B-Cell NHL

SEATTLE & SUMMIT, N.J.–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation (NASDAQ: CELG) today released additional data from the TRANSCEND study of JCAR017 (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma …
Share
7 December
Juno Signs Three Licensing Agreements to Advance its Multiple Myeloma Program with Gamma Secretase Inhibition

SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced three license agreements to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells. Gamma secretase is an enzyme that cleaves a …
Share

5 June
Juno Therapeutics Presents Updated Results for its CAR-T Candidate in Aggressive NHL

SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated data from the TRANSCEND trial of JCAR017 in relapsed and refractory (r/r) aggressive B cell non-Hodgkin lymphoma (NHL) in a presentation at the 2017 Annual Meeting of the American …
Share

20 December
FDA Grants Breakthrough Therapy Designation to Juno and Celgene’s JCAR017 in Lymphoma

SEATTLE & SUMMIT, N.J.–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO) and Celgene Corporation (NASDAQ: CELG), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational drug JCAR017 for the treatment of patients with relapsed/refractory (r/r) aggressive large B-cell non-Hodgkin lymphoma (NHL), including diffuse large …
Share
19 December
Juno Therapeutics Defeats Kite Pharma’s Challenge to CAR T-Cell Patent

SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it has defeated an attempt to invalidate a patent exclusively licensed by Juno that covers, among other things, a chimeric antigen receptor (CAR) T cell used for the treatment …
Share

9 September
Juno Announces Positive Data for its CAR-T Therapy from Early-Stage NHL Trial

SEATTLE–(BUSINESS WIRE)–Sep. 7, 2016– In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made …
Share

5 August
Juno Partners with Memorial Sloan Kettering and Eureka Therapeutics for CAR T Cell Therapy in Multiple Myeloma

SEATTLE & NEW YORK & EMERYVILLE, Calif.–(BUSINESS WIRE)–Aug. 4, 2016– Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center(MSK) and Eureka …
Share

14 July
Juno Therapeutics Acquires RedoxTherapies Gaining Access to its Early-Stage Immuno-Oncology Candidate

SEATTLE–(BUSINESS WIRE)–Jul. 14, 2016– Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced today that it has acquired RedoxTherapies, Inc., a privately held company based in Boston, Massachusetts. The acquisition provides Juno with an exclusive license to …
Share
13 July
FDA Removes Clinical Hold on Juno’s CAR-T Trial

SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, today announced that the U.S. Food and Drug Administration has removed the clinical hold on the Phase II clinical trial of JCAR015 (known as the “ROCKET” trial) in …
Share

Page 1 of 212 »